CLINICAL_TRIALS
trial_result
· 2013-10-07
Clinical Trial Update: Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL) [Phase 2]
Summary
Phase 2 trial of trastuzumab for HER2-positive relapsed/refractory B-acute lymphoblastic leukemia has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nantes University Hospital | Conditions: Relapsed/Refractory Leukemia | Phase 2 | Status: TERMINATED